Persistence of the "Hydralazine Syndrome"

Hildreth, Eugene A.; Biro, Carlos E.; McCreary, Thomas A.

doi:10.1001/jama.1960.03020240045009

Cited by 43 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La possibilità di sviluppare una sindrome lupica, però non dipende solamente dalla velocità di acetilazione ma anche dalla dose del farmaco e dall'antigene di istocompatibilità dell'ospite. Molti pazienti in terapia con idralazina sviluppano un DILE solo dopo aver assunto una dose totale di farmaco di 100 g (14). In realtà, la possibilità di sviluppare un DILE si associa alla presenza dell'antigene HLA-DR4, a dimostrazione del fatto che il DILE allo stesso modo del LES dipende da una predisposizione genetica (15).…”

Section: Prima Categoriaunclassified

Drug-induced lupus erythematosus

Atzeni¹,

Marrazza²,

Sarzi‐Puttini³

et al. 2011

Reumatismo

View full text Add to dashboard Cite

Drug-induced lupus is a syndrome which share symptoms and laboratory characteristics with the idiopathic systemic lupus erythematosus (SLE). The list of medications implicated as etiologic agents in drug-induced lupus continues to grow. The terms used for this condition are lupus-like syndrome, drug-induced lupus erythematosus (DILE) and drug related lupus. More than 80 drugs have been associated with DILE. The first case of DILE was reported in 1945 and associated with sulfadiazin. In 1953 it was reported that DILE was related to the use of hydralazine. Drugs responsible for the development of DILE can divided into three groups, but the list of these drugs is quite long because new drugs are included yearly in the list. The syndrome is characterised by arthralgia, myalgia, pleurisy, rash and fever in association with antinuclear antibodies in the serum. Recognition of DILE is important because it usually reverts within a few weeks after stopping the drug

show abstract

Section: Prima Categoriaunclassified

Drug-induced lupus erythematosus

Atzeni¹,

Marrazza²,

Sarzi‐Puttini³

et al. 2011

Reumatismo

View full text Add to dashboard Cite

show abstract

“…Hydralazine-induced SLE is frequently exacerbated and perhaps in some instances initiated by exposure to ultraviolet light (1,17). Further, in approximately 50 percent of patients idiopathic SLE flares up with exposure to the sun (1).…”

Section: April 1980mentioning

confidence: 99%

Hydralazine-Pyrimidine Interactions May Explain Hydralazine-Induced Lupus Erythematosus

Dubroff

Reid

1980

Science

View full text Add to dashboard Cite

Hydralazine, the prototypic drug that induces systemic lupus erythematosus, reacts with thymidine and deoxycytidine. Analysis of a reaction mixture of therapeutic concentrations of hydralazine with labeled thymidine reveals at least four labeled products. At higher concentrations, hydralazine reacts with labeled deoxycytidine to form at least three labeled products. Formation of these products is markedly enhanced by exposure to ultraviolet light. The reaction of hydralazine with thymidine and deoxycytidine may be in part responsible for initiating drug-induced systemic lupus erythematosus.

show abstract

“…Persisting symptoms particular artralgias have been reported (Alarcon-Segovia el al. , Hildreth et al 1960). Also antinuclear antibodies may remain for a long time (Condemi et al 1967).…”

Section: Clinical Picturementioning

confidence: 99%

Immunological Side‐effects of Antihypertensive Drugs

Holm¹

1979

Journal of Internal Medicine

View full text Add to dashboard Cite

Persistence of the "Hydralazine Syndrome"

Cited by 43 publications

References 9 publications

Drug-induced lupus erythematosus

Drug-induced lupus erythematosus

Hydralazine-Pyrimidine Interactions May Explain Hydralazine-Induced Lupus Erythematosus

Immunological Side‐effects of Antihypertensive Drugs

Contact Info

Product

Resources

About